Veracyte Inc VCYT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
-
Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors
-
Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
-
Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle
-
Veracyte Announces Second Quarter 2024 Financial Results
-
Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024
Trading Information
- Previous Close Price
- $33.51
- Day Range
- $33.47–34.85
- 52-Week Range
- $18.61–35.51
- Bid/Ask
- $32.11 / $35.43
- Market Cap
- $2.59 Bil
- Volume/Avg
- 1.5 Mil / 932,114
Key Statistics
- Price/Earnings (Normalized)
- 75.82
- Price/Sales
- 6.32
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Growth
- Total Number of Employees
- 815
- Website
- https://www.veracyte.com
Comparables
Valuation
|
Metric
|
VCYT
|
CSTL
|
BDSX
|
|---|---|---|---|
Price/Earnings (Normalized) | 75.82 | 232.91 | — |
Price/Book Value | 2.29 | 1.82 | 6.85 |
Price/Sales | 6.32 | 2.69 | 2.78 |
Price/Cash Flow | 37.42 | 14.64 | — |
Price/Earnings
VCYT
CSTL
BDSX
Financial Strength
|
Metric
|
VCYT
|
CSTL
|
BDSX
|
|---|---|---|---|
Quick Ratio | 3.96 | 7.75 | 2.98 |
Current Ratio | 4.44 | 8.12 | 3.28 |
Interest Coverage | −13,015.40 | −54.71 | −3.85 |
Quick Ratio
VCYT
CSTL
BDSX
Profitability
|
Metric
|
VCYT
|
CSTL
|
BDSX
|
|---|---|---|---|
Return on Assets (Normalized) | 9.55% | 7.97% | −39.52% |
Return on Equity (Normalized) | 10.25% | 9.08% | −685.43% |
Return on Invested Capital (Normalized) | 9.19% | 6.49% | −45.23% |
Return on Assets
VCYT
CSTL
BDSX
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| Vsfwmpxxgb | Qxh | $234.7 Bil | |||
| Danaher Corp
DHR
| Vccrhwqz | Pdnxtd | $198.9 Bil | |||
| IQVIA Holdings Inc
IQV
| Fqldvcszz | Rlxjj | $42.8 Bil | |||
| Agilent Technologies Inc
A
| Yrcmcbnrt | Xjntw | $42.5 Bil | |||
| IDEXX Laboratories Inc
IDXX
| Mcfbkckf | Cmfm | $42.1 Bil | |||
| Mettler-Toledo International Inc
MTD
| Xzjmbtnzfq | Sqrcyt | $31.4 Bil | |||
| Icon PLC
ICLR
| Nmbtydfbs | Kzjngc | $23.7 Bil | |||
| Waters Corp
WAT
| Bgshrfbqk | Wjn | $21.2 Bil | |||
| Illumina Inc
ILMN
| Xskynmx | Jtvsqv | $20.7 Bil | |||
| Labcorp Holdings Inc
LH
| Csjbpytgsm | Scvgm | $18.6 Bil |
United States